Fulltext

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer

Adams, Olivia Joan ; Stanczak, Michal A. ; von Gunten, Stephan ; Läubli, Heinz

In: Glycobiology, 2018, vol. 28, no. 9, p. 640-647

Ajouter à la liste personnelle
    Titre
    • Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer
    Auteur
    • Adams, Olivia Joan. Institute of Pharmacology, University of Bern, Inselspital INO-F, Bern, Switzerland
    • Stanczak, Michal A.. Laboratory of Cancer Immunology, Department of Biomedicine
    • von Gunten, Stephan. Institute of Pharmacology, University of Bern, Inselspital INO-F, Bern, Switzerland
    • Läubli, Heinz. Laboratory of Cancer Immunology, Department of Biomedicine
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Glycobiology, 2018, vol. 28, no. 9, p. 640-647. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:332083
    Summary
    Changes in sialic acids in cancer have been observed for many years. In particular, the increase of sialoglycan density or hypersialylation in tumors has been described. Recent studies have identified mechanisms for immune evasion based on sialoglycan interactions with immunoregulatory Siglec receptors that are exploited by tumor cells and microorganisms alike. Siglecs are mostly inhibitory receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted with blocking antibodies for cancer immunotherapy. Here, we summarize the known changes of sialic acids in cancer and the role Siglec receptors play in cancer immunity. We also focus on potential ways to target these Siglec receptors or sialoglycans in order to improve anti-cancer immunity.